Section 4 of 6
Clinical evidence
329 evidence topics · 58 sources
Study summaries
Integrated externally controlled survival analysis
Objective
Objectives of the company-presented survival analysis with broader external controls
Objectives proposed in the 2021 data request for external controls
Objective of the NIH natural history study used as the external control
Location and study date
Data cutoff of the company-presented survival analysis, January 2025
International registry and French cohort contributing external controls
Database lock of the prior sponsor's studies, December 2021
Data cutoff of the company-presented survival analysis, September 2025, superseded in February 2026
Study design
Integrated survival analysis as the basis of effectiveness in the label
FDA determination that the externally controlled comparison was the adequate and well-controlled study
Externally controlled analysis submitted as a single adequate and well-controlled study
Design rationale stated in the 2021 data request
Company-presented survival analysis with broader external controls: data sources
Company-presented survival analysis with broader external controls: target trial emulation
Company-presented disease progression analysis in treated participants
Company-presented survival analysis matching, September 2025, superseded in February 2026
Eligibility criteria
Neurological onset before 6 years of age in the label analysis
Company-presented survival analysis with broader external controls: eligibility for matching
Inclusion and exclusion criteria proposed in the 2021 data request
Treatment
Treatment exposure and dosage in the label analysis
Company-presented survival analysis with broader external controls: dosing across source studies
Company-presented survival analysis with broader external controls: concomitant NPC therapies
Treatment definition proposed in the 2021 data request
Study outcomes
Rationale for using overall survival as the primary endpoint
Overall survival definition in the label analysis
Survival as an outcome in very young children with the fastest progression
Age of neurological onset as the predictor of survival
Secondary measure in the company-presented analysis: rescored 4-domain NPC Clinical Severity Scale
Statistical analysis description
Number of participants (Planned and analyzed)
Treated and external control participants in the label analysis
Company-presented survival analysis with broader external controls: 72 treated and 119 matched controls
Company-presented survival analysis with 66 treated and 110 matched controls, September 2025, superseded in February 2026
Description of analysis sets
Index age, weighting, and statistical models in the label analysis
Company-presented survival analysis with broader external controls: statistical models and censoring
Company-presented survival analysis with broader external controls: matching with replacement and robust variance
Company-presented survival analysis with broader external controls: prespecified subgroup analyses
| Subgroup analysis | Definition |
|---|---|
| Baseline miglustat use | “Participants with and without baseline miglustat use” |
| Source of external control data | “NIH, YODA, and French cohorts considered separately” |
| Age of neurological onset | “Early and late I-NPC subgroups considered separately” |
| Standard-of-care therapy over time | “Participants born before 2010 and born in 2010 or later” |
Company-presented survival analysis with broader external controls: sensitivity analyses
Survival model proposed in the 2021 data request
Results
Participant disposition
Source studies of the treated participants and follow-up in the label analysis
Company-presented survival analysis with broader external controls: movement of participants between source studies
Baseline characteristics
Baseline characteristics of treated and matched external control participants in the label analysis
Company-presented survival analysis with broader external controls: baseline characteristics of 72 treated and 119 matched controls
| Characteristic | Adrabetadex (N=72) | External control (N=119) |
|---|---|---|
| Age at onset under 2 years, n/N (%) | “32/72 (44)” | “57/119 (48)” |
| Age at onset 2 to under 6 years, n/N (%) | “40/72 (56)” | “62/119 (52)” |
| Median age at neurological onset, months (Q1, Q3) | “25 (0, 68)” | “24 (0, 68)” |
| Overall miglustat use, n/N (%) | “52/72 (72)” | “72/119 (61)” |
| Gastrostomy tube, n/N (%) | “11/50 (22)” | “6/26 (23)” |
| Respiratory therapy, n/N (%) | “9/50 (18)” | “2/26 (8)” |
| Race White, n/N (%) | “65/72 (90)” | “22/26 (85)” |
| Race other, n/N (%) | “7/72 (10)” | “4/26 (15)” |
| Region Europe, n/N (%) | “11/72 (15)” | “90/119 (76)” |
| Region North America, n/N (%) | “61/72 (85)” | “27/119 (23)” |
| Region South America, n/N (%) | “0 (0)” | “2/119 (2)” |
Efficacy results
Overall survival in the label integrated survival analysis
| Outcome | LEMBAZ (N=36) | External control (N=36) |
|---|---|---|
| Number of deaths (%) | “12 (33.3%)” | “24 (66.9%)” |
| Median survival time in months | “102” | “59” |
| Hazard ratio for risk of death (95% CI) | “0.45 (0.21, 0.95)” | Reference |
Overall survival as stated by the FDA
Company-presented survival analysis with broader external controls: overall survival in 72 treated and 119 matched controls
| Population and comparator source | Deaths, adrabetadex (%) | Deaths, external control (%) | HR (95% CI) | P-value |
|---|---|---|---|---|
| Overall infantile | “17 (23.6%)” | “44 (61.2%)” | “0.289 (0.141, 0.593)” | “< 0.0001” |
| Early infantile | “9 (28.1%)” | “24 (76.1%)” | “0.148 (0.064, 0.343)” | “< 0.0001” |
| Late infantile | “8 (20.0%)” | “20 (49.2%)” | “0.344 (0.146, 0.812)” | “0.0457” |
| With miglustat | “8 (22.9%)” | “13 (37.9%)” | “0.361 (0.173, 0.752)” | “0.0205” |
| Without miglustat | “7 (33.3%)” | “19 (91.2%)” | “0.139 (0.049, 0.398)” | “< 0.0001” |
| French comparator | “9 (16.4%)” | “44 (80.7%)” | “0.113 (0.042, 0.301)” | “< 0.0001” |
| NIH comparator | “12 (33.3%)” | “30 (84.2%)” | “0.449 (0.214, 0.946)” | “0.0322” |
| YODA comparator | “8 (21.6%)” | “6 (16.4%)” | “0.381 (0.128, 1.137)” | “0.1426” |
Company-presented survival analysis with broader external controls: hazard ratio and five-year survival as announced
Company-presented survival analysis with broader external controls: consistency across sensitivity analyses
Company-presented disease progression analysis: annual rate of change on the rescored 4-domain NPC Clinical Severity Scale
Company-presented survival analysis with 66 treated and 110 matched controls, September 2025, superseded in February 2026
| Population and comparator source | Deaths, treated (%) | Deaths, control (%) | Hazard ratio (95% CI) | P-value |
|---|---|---|---|---|
| Overall infantile, pooled comparator | “9 (13.6%)” | “42 (63.3%)” | “0.162 (0.069, 0.380)” | “<0.0001” |
| Early infantile, pooled comparator | “6 (18.8%)” | “23 (72.8%)” | “0.109 (0.035, 0.333)” | “<0.0001” |
| Late infantile, pooled comparator | “3 (8.8%)” | “18 (54.3%)” | “0.148 (0.040, 0.546)” | “0.0036” |
| With miglustat | “2 (7.1%)” | “12 (41.8%)” | “0.097 (0.023, 0.406)” | “0.0005” |
| Without miglustat | “5 (21.7%)” | “18 (79.9%)” | “0.123 (0.036, 0.425)” | “<0.0001” |
| French comparator | “5 (9.8%)” | “42 (82.1%)” | “0.073 (0.023, 0.236)” | “<0.0001” |
| NIH comparator | “5 (15.2%)” | “24 (71.2%)” | “0.176 (0.060, 0.517)” | “<0.0001” |
| YODA comparator | “4 (11.4%)” | “6 (17.9%)” | “0.298 (0.082, 1.086)” | “0.1168” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: limitations of the integrated externally controlled survival analysis
- Design: the comparison is with external controls. A statistical methods poster on the analysis states that externally controlled analyses are susceptible to bias from differences in baseline prognosis, treatment initiation at different ages, calendar time and standards of care, and post-baseline therapies, and that target trial emulation identified four principal threats: prognostic factor confounding, post-baseline treatment confounding, immortal time bias, and temporal bias. Both the label analysis and the company analysis required each matched control to be alive at the treated participant's age at treatment initiation.
- Label analysis: all 26 external control participants came from Study 1 and were weighted to a number of 36 against 36 treated participants. Matching used disease subtype, age of neurological symptom onset (±3 months), and baseline miglustat use; 58% of treated and 33% of control participants were male, median follow-up from the index age was 5.6 and 4.2 years, and index ages ranged from 1 to 19 years. The label states that safety and effectiveness in reducing mortality with neurological onset at 6 years of age or older has not been established.
- Analysis with broader external controls: 72 treated participants were matched with 119 external controls drawn from 4 major disease databases or publications, and the poster states that comparability factors were not available from all sources.
- Variation in the estimate: the hazard ratio differed by comparator source (French 0.113; NIH 0.449, 95% CI 0.214 to 0.946; YODA 0.381, 95% CI 0.128 to 1.137, P = 0.1426) and between data cuts (0.162 with 66 treated participants at the June 24, 2024 cutoff; 0.289 with 72 at the January 10, 2025 cutoff). The label analysis reported 0.45 (0.21, 0.95). The statistical methods poster reported that hazard ratio estimates across its prespecified sensitivity analyses remained consistent with the primary analysis.
- Analysis plan: the YODA Project data request that proposed the external control analysis stated that “All planned statistical analyses are exploratory” and that no minimum sample size was determined a priori.
Indication limited to neurological onset before 6 years of age
Sources of bias in externally controlled survival analyses
Incomplete comparability data across external control sources
VTS301 parts A and B
Objective
Primary objectives of Parts A and B
Objective of the post hoc cerebrospinal fluid biomarker analysis
Location and study date
Registry study dates and enrollment
| Field | Quoted record |
|---|---|
| Study start (actual) | “2015-10” |
| Primary completion (actual) | “2018-03-28” |
| Study completion (actual) | “2018-03-28” |
| Enrollment (actual) | “56” |
| Results first posted | “2023-02-22” |
Study sites by country
Planned number of sites and regulatory oversight
| Field | Quoted record |
|---|---|
| Number of Sites | “Approximately 24 sites worldwide” |
Study design
Multicenter, randomized, double-blind, sham-controlled three-part design
Label description of Trial 1 Parts A and B
Randomization ratios, dose selection, and rescue option
“In Part A, 12 subjects were randomly assigned to one of four study arms (1:1:1:1), and received either one of three dose levels of adrabetadex (900 mg, 1200 mg, or 1800 mg per IT via LP) or sham procedure (no lumbar puncture).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following dose selection in Part A, 44 additional subjects were randomized 2:1 to receive either study drug at the dose level chosen in Part A (900 mg) or sham.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subjects enrolled in Part B who manifested significant disease progression according to predefined clinical criteria after treatment of 26 weeks or more had the option to escape the blinded trial early and enter Part C.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose selection committee and stratification of Part B randomization
Sham procedure and blinding
Sponsor rationale for the sham control
Duration of participation in Parts A and B
Eligibility criteria
Age, age at neurological onset, and diagnosis
Disease severity required at entry
Body weight, prior cyclodextrin, and antipsychotic exclusions
Washout of supplements and investigational treatments
Treatment
Dosage by part in the label
Dose reduction for drug-related adverse events
Intrathecal administration procedure
Sham control intervention in the registry
Study outcomes
Rationale for using the 4-Item NPC severity scale composite score as a co-primary endpoint
Co-primary endpoints: NPC-SS composite score and clinician CGIC at Week 52
Scoring of the 4-item composite and the clinician CGIC
Key secondary endpoints as revised in the statistical analysis plan
Selection of the 4-item composite score for this trial
“Vtesse, Inc., now a Mallinckrodt Pharmaceuticals company, selected the four-item composite score as the primary efficacy endpoint in the Phase 2/3 multicenter clinical trial of intrathecal adrabetadex in NPC1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The NPC-SS and particularly the 4- and 5-item scales represent key domains identified by families and clinicians as important to quality of life.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All domains were rated except those involving hearing as hearing information was being monitored seperately in the trial to track this as an adverse event, the hearing rating was not part of the efficacy score as the drug can cause hearing loss, and hearing information might have unblinded the NPC-SS raters to treatment status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Inter-rater reliability of central NPC-SS scoring in this trial
“The objective of the study was to examine the inter-rater reliability of the NPC-SS in a Phase 2/3 clinical trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinical data recorded at each study site were distributed to two independent blinded central raters to generate a severity score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average ICCs for absolute agreement for the 4-item and 5-item scales, respectively, were ICC (3,2) = 0.95 [95% CI = 0.93, 0.97] and 0.96 [95% CI = 0.93, 0.97] for the multiple assessment, and ICC (3,1) = 0.91 [95% CI = 0.87, 0.94] and 0.92 [95% CI = 0.87, 0.94] for the single assessment (Supplemental Data, Table 9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the NPC-SS 4-item composite score, the average kappa was 0.36 [95% CI= 0.31, 0.42], the average weighted kappa was 0.76 [95% CI= 0.73, 0.79], and the average percent agreement between raters was 40.9% (95% CI= 35.2, 46.6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These results support the NPC-SS, including derived 4- and 5-item composite scores, as reliable measures for use in a clinical trial setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Development of the NPC clinical severity scale
“Thus, we developed a clinical severity scale to characterize and quantify disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both patient cohorts showed a linear increase in severity scores over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Content validity and meaningful change of the 5-domain scale
“Domains identified as most important by clinicians, caregivers, and patients (independent of current age, age of onset, and disease severity) were Ambulation, Swallow, Cognition, Speech, and Fine Motor Skills, indicating content validity of the 5-domain NPCCSS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Meaningful change using trial data and interviews with NPC experts (n = 5) and patients/caregivers (n = 28) suggested that a 1-category change on a domain is equivalent to 1-point change or greater in the 5-domain NPCCSS total score.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
International Delphi consensus on severity scales
“Consensus was reached (74%) for the 17-domain NPCCSS scale as the first choice in clinical trial settings, but the domains measured in the 5-domain scale should be prioritised as the primary endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Several scales have been developed and published over the past two decades but, essentially, all are based on a four-domain scale initially developed by Iturriaga et al.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Convergent validity of scale domains, including data from this trial
“Participants were drawn from several studies performed at two sites at which participants with clinically and biochemically confirmed NPC were followed with regular clinical evaluations, including a natural history study for NPC (NCT00344331), a phase 1/2a trial of intrathecal 2-hydroxypropyl-beta-cyclodextrin (adrabetadex, NCT01747135), a phase 2b/3 trial of adrabetadex (NCT02534844), and an expanded access program for treatment of NPC with adrabetadex (IND119856).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 5DNPCCSS domains were significantly related in the expected directions to their respective direct assessments, supporting their construct validity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the years since its publication, researchers and regulators have noted that the wide-ranging composition of the NPC-CSS-17, meant to capture the full range of clinical presentation, might reduce its ability to detect an effect of intervention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and its basis
Power calculation assumptions
Description of analysis sets
Analysis populations in the protocol
Modified intent-to-treat population as defined in the statistical analysis plan
Analysis populations in the registry results
Primary analysis method and handling of missing data
Clinician CGIC analysis and hierarchical testing of key secondary endpoints
Statistical methods of the post hoc biomarker analysis
Results
Participant disposition
Participant flow in the ClinicalTrials.gov record
Baseline characteristics
Baseline demographics of the intent-to-treat population in the ClinicalTrials.gov record
Baseline weight, miglustat use, seizures, symptom duration, and total severity score
| Characteristic | Adrabetadex (N=38) | Sham control (N=18) |
|---|---|---|
| Weight (kg), mean (SD) | “48.1 (25.27)” | “40.2 (18.98)” |
| Miglustat use, n (%) | “25 (66)” | “9 (50)” |
| Seizures, n (%) | “15 (39)” | “5 (28)” |
| Duration of neurologic symptoms (years), mean (SD) | “7.1 (4.15)” | “5.9 (5.16)” |
| Baseline NPC-CSS total score (minus hearing/ABR), mean (SD) | “17.8 (6.48)” | “16.9 (8.16)” |
Label demographics of participants receiving up to 900 mg and sham
Cerebrospinal fluid biomarker analysis subset
Efficacy results
Sponsor statements of the Parts A and B result
Secondary endpoints reported in the ClinicalTrials.gov results
| Outcome measure | Sham control | Adrabetadex |
|---|---|---|
| NPC-SS total score excluding hearing and ABR, change at Week 52, mean (SD) | “-0.74(2.357)” | “-0.34(4.226)” |
| Responders on NPC-SS total score excluding hearing and ABR at Week 52, participants | “13” | “22” |
| Participants who qualified for the rescue option | “2” | “2” |
| Time to one-point worsening in NPC-SS composite score, median days (95% CI) | “118 (55 to 364)” | “169 (70 to 278)” |
| 9-Hole Peg Test, change at Week 52, seconds, mean (SD) | “-1.49(15.958)” | “-1.79(34.760)” |
| Annualized rate of change (slope) of NPC-SS composite, mean (SD) | “-0.05(1.640)” | “0.08(2.441)” |
Timed Up and Go test and total NPC-SS including hearing
| Outcome measure | Sham control | Adrabetadex |
|---|---|---|
| Timed Up and Go, change at Week 52, seconds, mean | “0.86” | “2.70” |
| Timed Up and Go, change at Week 52, seconds, SD | “19.232” | “9.633” |
| Total NPC-SS with hearing and ABR, change at Week 52, mean | “0.000” | “0.75” |
| Total NPC-SS with hearing and ABR, change at Week 52, SD | “1.000” | “4.500” |
Change in each NPC-SS domain at Week 52
| Domain, change from baseline at Week 52 | Sham control, mean | Sham control, SD | Adrabetadex, mean | Adrabetadex, SD |
|---|---|---|---|---|
| Ambulation | “0.00” | “0.679” | “0.06” | “1.434” |
| Fine motor | “0.07” | “0.917” | “0.24” | “1.103” |
| Cognition | “-0.14” | “0.663” | “0.06” | “0.919” |
| Swallowing | “0.00” | “1.109” | “-0.29” | “1.360” |
| Memory | “0.00” | “0.784” | “0.18” | “1.218” |
| Speech | “0.14” | “0.663” | “-0.18” | “0.673” |
| Eye movement | “0.00” | “0.679” | “-0.06” | “0.547” |
| Hearing | “-0.22” | “1.302” | “1.14” | “1.236” |
| Seizures | “-0.50” | “1.286” | “-0.06” | “0.952” |
Post hoc cerebrospinal fluid biomarkers at Week 52 in adrabetadex-treated participants
Health-related quality of life and patient-reported outcomes
Caregiver-rated CGIC responders at Week 52
Safety results
Deaths, serious adverse events, and other adverse events by arm
| Event | Part A adrabetadex 900 mg | Part A adrabetadex 1200 mg | Part A adrabetadex 1800 mg | Part A sham | Part B adrabetadex 900 mg | Part B sham |
|---|---|---|---|---|---|---|
| All-cause mortality | “0/3 (0.00%)” | “0/3 (0.00%)” | “1/3 (33.33%)” | “0/3 (0.00%)” | “0/29 (0.00%)” | “1/15 (6.67%)” |
| Any serious adverse event | “1/3 (33.33%)” | “0/3 (0.00%)” | “2/3 (66.67%)” | “0/3 (0.00%)” | “16/29 (55.17%)” | “3/15 (20.00%)” |
| Any other (non-serious) adverse event | “3/3 (100.00%)” | “3/3 (100.00%)” | “3/3 (100.00%)” | “3/3 (100.00%)” | “28/29 (96.55%)” | “14/15 (93.33%)” |
Serious adverse events of hearing, seizure, and aspiration in Part B
| Serious adverse event | Part B adrabetadex 900 mg | Part B sham |
|---|---|---|
| Deafness | “3/29 (10.34%)” | “0/15 (0.00%)” |
| Hearing impaired | “3/29 (10.34%)” | “1/15 (6.67%)” |
| Seizure | “3/29 (10.34%)” | “1/15 (6.67%)” |
| Aspiration | “2/29 (6.90%)” | “1/15 (6.67%)” |
| Pneumonia aspiration | “3/29 (10.34%)” | “0/15 (0.00%)” |
Common non-serious adverse events in Part B
| Adverse event | Part B adrabetadex 900 mg | Part B sham |
|---|---|---|
| Vomiting | “15/29 (51.72%)” | “2/15 (13.33%)” |
| Back pain | “14/29 (48.28%)” | “0/15 (0.00%)” |
| Fatigue | “12/29 (41.38%)” | “2/15 (13.33%)” |
| Pyrexia | “12/29 (41.38%)” | “3/15 (20.00%)” |
| Gait disturbance | “11/29 (37.93%)” | “2/15 (13.33%)” |
| Hypoacusis | “10/29 (34.48%)” | “0/15 (0.00%)” |
| Fall | “10/29 (34.48%)” | “1/15 (6.67%)” |
| Diarrhoea | “9/29 (31.03%)” | “1/15 (6.67%)” |
| Headache | “9/29 (31.03%)” | “1/15 (6.67%)” |
| Hearing impaired | “8/29 (27.59%)” | “6/15 (40.00%)” |
| Nausea | “8/29 (27.59%)” | “0/15 (0.00%)” |
| Ataxia | “7/29 (24.14%)” | “2/15 (13.33%)” |
| Tinnitus | “5/29 (17.24%)” | “0/15 (0.00%)” |
Company summary of safety in the Parts A and B safety population
Study limitations
Summary: design limitations of Parts A and B
- Control and observed progression: Parts A and B compared intrathecal VTS-270 with a sham procedure of 1 to 2 small needle pricks on the lower back with no lumbar puncture. At Week 52 the mean change from baseline in the NPC-SS composite score was -0.1 (SD 1.55) in the sham group (n = 18) and 0.0 (SD 2.45) in the adrabetadex group (n = 38). The company stated that “Neither the VTS-270 nor the placebo arm showed disease progression”, and a data request summary states that the trial failed to show benefit “as the sham group had little progression” and that sham-controlled trials in NPC “are highly challenging due to variability of the disease”.
- Blinding: the participant, outcomes assessor, care provider, and investigator were blinded. The hearing rating was excluded from the efficacy score because the drug can cause hearing loss and “hearing information might have unblinded the NPC-SS raters to treatment status”. NPC-SS scores were generated by two central raters, which the inter-rater reliability study lists as a limitation.
- Sample size: the sample size was based on the potential number of available subjects for this ultra-rare disorder. The plan of approximately 51 subjects gave the ANCOVA 79% power under assumed 52-week increases of 0 to 0.2 points with VTS-270 and 1.6 to 1.9 points with sham. The statistical analysis plan states that 54 subjects were randomized; the prescribing information states that Parts A and B enrolled 56 treatment-naïve participants.
- Randomization ratio: one publication states that Part A randomized 12 subjects 1:1:1:1 to three dose levels or sham, and protocol amendment 15 states a 3:1 ratio in Part A. Both state a 2:1 ratio in Part B.
- Analysis sets: the registry analyzed 38 adrabetadex and 18 sham participants for the co-primary NPC-SS composite endpoint and 34 and 14 for the annualized slope. The prescribing information describes 32 participants who received up to 900 mg and 18 in the sham-control group. The statistical analysis plan restricts the modified intent-to-treat population to subjects who received at least one dose of 900 mg of VTS-270 or sham control, and the registry defines it as all randomized participants who received at least one treatment (sham or adrabetadex). The statistical analysis plan also changed the protocol's list of key secondary endpoints.
- Early exit: Part B participants with significant disease progression after 26 weeks or more could leave the blinded trial early and enter Part C; 2 sham and 2 adrabetadex participants qualified for this rescue option.
- Concomitant miglustat: randomization in Part B was stratified by miglustat use and baseline NPC-SS level, but the statistical analyses were not stratified. At baseline, 25 (66%) adrabetadex and 9 (50%) sham participants used miglustat. A post hoc analysis reported that subjects receiving miglustat, with or without adrabetadex, showed evidence of disease stabilization, while subjects receiving adrabetadex without miglustat showed disease worsening comparable to sham subjects not on miglustat.
- Biomarkers: cerebrospinal fluid was collected only from subjects receiving study drug; sham-control subjects provided urine and plasma. The post hoc biomarker study of 34 participants tested within-group changes with the Wilcoxon signed-rank test, with nominal significance at P<0.05 without adjustment for multiplicity.
- Sponsor statements: the company stated that it was evaluating this portion of the study “in order to ensure the data was properly captured and of the highest quality”. A community update stated that a manuscript summarizing the data and experience from the VTS-301 trial was being prepared.
Little progression in the sham group
No cerebrospinal fluid collection from sham-treated participants
Planned trial manuscript, May 2022
VTS301 part C
Objective
Primary objective of Part C, before and after January 2021
Secondary objective: intrathecal access device substudy
Location and study date
Registry study dates and enrollment
| Field | Quoted record |
|---|---|
| Study start (actual) | “2015-12-23” |
| Primary completion (actual) | “2022-04-11” |
| Study completion (actual) | “2022-04-11” |
| Enrollment (actual) | “66” |
| Results first posted | “2023-08-29” |
Number of locations and facilities in Washington, DC and Switzerland
| Country | Facility |
|---|---|
| United States | “Children's National Medical Center” |
| Switzerland | “INSELSPITAL, Universitätsspital Bern” |
End of dosing in 2021
VTS-270-302: registry dates and site in Costa Rica
| Field | Quoted record |
|---|---|
| Study start (actual) | “2019-12-02” |
| Study completion (actual) | “2021-10-18” |
| Enrollment (actual) | “2” |
| Location | “Hospital Clinica Biblica” |
Study design
Open-label, single-group extension
Efficacy endpoints planned for Part C
Device substudies and termination of enrollment
VTS-270-302: open-label continuation study for VTS301 participants
Eligibility criteria
Routes of entry into Part C
Conditions for continuing treatment after 21 June 2021
VTS-270-302 inclusion criteria
Treatment
Dosage in Part C
Dose re-escalation and reduction in Part C
Dosing of participants from the NIH phase 1/2a trial
Rationale for the intrathecal access port
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Open-label population
Results
Participant disposition
Participant flow and reasons for not completing
| Milestone or reason | Treatment naive | Previously treated in phase I | Previously treated in Part A/B |
|---|---|---|---|
| Started | “18” | “13” | “35” |
| Completed | “0” | “0” | “0” |
| Not completed | “18” | “13” | “35” |
| Adverse event | “1” | “0” | “1” |
| Death | “0” | “0” | “1” |
| Investigator's decision | “0” | “0” | “1” |
| Lost to follow-up | “1” | “0” | “0” |
| Termination by sponsor or regulatory authorities | “8” | “4” | “13” |
| Transferred to EAP following study termination | “0” | “0” | “1” |
| Transferred to Expanded Access Program | “1” | “0” | “0” |
| Transferred to OLEX program | “3” | “0” | “5” |
| Withdrawal by subject | “4” | “9” | “13” |
Recorded reason the study stopped
| Field | Quoted record |
|---|---|
| Why stopped | “Terminated by previous Sponsor decision” |
Baseline characteristics
Baseline demographics by entry group
| Characteristic | Treatment naive (n = 18) | Previously treated in phase I (n = 13) | Previously treated in Part A/B (n = 35) | Total (n = 66) |
|---|---|---|---|---|
| Age, years, mean (SD) | “13.2(5.07)” | “17.5(6.16)” | “14.1(5.60)” | “14.5(5.70)” |
| Female | “10” | “7” | “15” | “32” |
| Male | “8” | “6” | “20” | “34” |
| White | “16” | “13” | “29” | “58” |
| Hispanic or Latino | “3” | “1” | “2” | “6” |
VTS-270-302 baseline reporting
Efficacy results
Efficacy endpoints not reported after January 2021
VTS-270-302: efficacy assessments discontinued
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Deaths and serious adverse events
| Event | Treatment naive | Previously treated in phase I | Previously treated in Part A/B |
|---|---|---|---|
| All-cause mortality | “1/18 (5.56%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Any serious adverse event | “9/18 (50.00%)” | “7/13 (53.85%)” | “20/35 (57.14%)” |
| Dysphagia | “1/18 (5.56%)” | “0/13 (0.00%)” | “4/35 (11.43%)” |
| Pneumonia aspiration | “1/18 (5.56%)” | “0/13 (0.00%)” | “3/35 (8.57%)” |
| Pneumonia | “1/18 (5.56%)” | “2/13 (15.38%)” | “1/35 (2.86%)” |
| Back pain | “3/18 (16.67%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Deafness neurosensory | “1/18 (5.56%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Meningitis bacterial | “0/18 (0.00%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Meningitis staphylococcal | “0/18 (0.00%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Spinal subdural haematoma | “1/18 (5.56%)” | “0/13 (0.00%)” | “0/35 (0.00%)” |
| Spinal subarachnoid haemorrhage | “0/18 (0.00%)” | “0/13 (0.00%)” | “1/35 (2.86%)” |
| Device dislocation | “0/18 (0.00%)” | “0/13 (0.00%)” | “2/35 (5.71%)” |
Common non-serious adverse events
| Adverse event | Treatment naive | Previously treated in phase I | Previously treated in Part A/B |
|---|---|---|---|
| Any other (non-serious) adverse event | “18/18 (100.00%)” | “13/13 (100.00%)” | “34/35 (97.14%)” |
| Vomiting | “12/18 (66.67%)” | “9/13 (69.23%)” | “16/35 (45.71%)” |
| Hypoacusis | “9/18 (50.00%)” | “4/13 (30.77%)” | “9/35 (25.71%)” |
| Headache | “9/18 (50.00%)” | “9/13 (69.23%)” | “12/35 (34.29%)” |
| Ataxia | “9/18 (50.00%)” | “2/13 (15.38%)” | “8/35 (22.86%)” |
| Fatigue | “8/18 (44.44%)” | “5/13 (38.46%)” | “13/35 (37.14%)” |
| Pyrexia | “6/18 (33.33%)” | “9/13 (69.23%)” | “17/35 (48.57%)” |
| Fall | “5/18 (27.78%)” | “7/13 (53.85%)” | “16/35 (45.71%)” |
| Gait disturbance | “2/18 (11.11%)” | “6/13 (46.15%)” | “10/35 (28.57%)” |
Termination of device implantation after catheter tip migration
VTS-270-302 safety
| Outcome | Adrabetadex (n = 2) |
|---|---|
| All TEAEs, participants | “2” |
| SAEs, participants | “0” |
| All-cause mortality | “0/2 (0.00%)” |
Study limitations
Summary: design limitations of Part C
- Control and blinding: Part C was an open-label extension in which all participants received study drug, and the sponsor gave it a separate registration because of its different study design.
- Mixed population and dosing: Part C enrolled 66 participants, comprising 35 LEMBAZ-treated participants from Parts A and B, 18 treatment-naïve participants, and 13 LEMBAZ-treated patients from Trial 2. The dose could be adjusted between 400 mg and 900 mg at the investigator's discretion, and rollover participants from Study 13-CH-0001 received an amended dose and/or regimen.
- Missing efficacy collection: the planned efficacy endpoints included the NPC-SS composite and the EQ-5D-3L. Following a determination of a negative benefit/risk balance on 20 January 2021, the objective of Part C was changed to longer-term safety and tolerability only, and efficacy endpoints after 20 January 2021 were not reported.
- Early termination: the sponsor discontinued the development program and terminated Part C. No participant completed the study (0 of 18 treatment-naive, 0 of 13 previously treated in phase I, and 0 of 35 previously treated in Part A/B); termination by sponsor or regulatory authorities accounted for 8, 4, and 13 participants and withdrawal by subject for 4, 9, and 13.
- Selective continuation: after 21 June 2021, only subjects who appeared to be benefiting in the investigator's assessment, and who understood that no significant differences were seen between adrabetadex and sham on any efficacy measure in the randomized trial, could continue treatment.
- Substudies: the planned European plasma and CSF pharmacokinetic substudy of administration through the device was not conducted because no subjects consented.
- VTS-270-302 continuation study: planned for approximately 7 subjects, it enrolled 2, was terminated early by the sponsor, did not perform efficacy assessments or analyze existing efficacy data, and reported no baseline data to maintain participant confidentiality.
Termination of Part C by the sponsor
VTS-270-001
Objective
Registered objective: long-term safety and effectiveness
Protocol primary and secondary objectives
| Objective | Protocol text |
|---|---|
| Primary objective | “To evaluate the longer-term safety and tolerability of adrabetadex administered IT via LP every 2 weeks” |
| Secondary objective | “To summarize additional longer-term safety and tolerability of adrabetadex administered IT via LP every 2 weeks” |
Location and study date
Registry study dates
| Field | Registry record |
|---|---|
| Study start (actual) | “2018-06-18” |
| Primary completion (actual) | “2021-11-02” |
| Study completion (actual) | “2021-11-02” |
| First posted | “2018-08-23” |
| Results first posted | “2024-01-17” |
Study sites in the United States
Protocol dates and end of treatment in October 2021
| Field | Protocol text |
|---|---|
| Original protocol | “Date of Original Protocol: 01 December 2017” |
| Protocol amendment 3 | “Date of Protocol Amendment 3: 23 June 2021” |
Study design
Open-label single-arm trial in treatment-naive and previously treated participants
Registry design fields and conversion from expanded access
| Field | Registry record |
|---|---|
| Official title | “Open-label Evaluation of Adrabetadex in Patients With Neurologic Manifestations of Niemann-Pick Type C Disease (NPC)” |
| Other study ID | “VTS-270-001” |
| Study type | “Interventional” |
| Phase | “Phase 3” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Interventional model description | “Continued treatment for children at least 4 years of age” |
| Masking | “None (Open Label)” |
Protocol design: prospective open-label safety study without a control group
Protocol amendment 3: sponsor recommendation to discontinue treatment and benefit assessment for continuation
Eligibility criteria
Registry inclusion criteria
Protocol criteria for participants already receiving adrabetadex and for hydrocephalus
Treatment
Starting dosage by prior treatment status
Registry arm description and treatment duration
Protocol dose preparation and lumbar puncture administration
Protocol dose adjustment rules and dose increases stopped in April 2021
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Registered primary outcome measure
| Field | Registry record |
|---|---|
| Outcome measure | “Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)” |
| Time frame | “Baseline up to Week 134” |
Registry definition of treatment-emergent and serious adverse events
Protocol primary and secondary safety endpoints
| Endpoint | Protocol text |
|---|---|
| Primary endpoint | “Summary of TEAEs, SAEs, discontinuation due to TEAEs, and deaths” |
| Secondary endpoint | “Change in audiologic testing.” |
| Secondary endpoint | “Laboratory changes from baseline (hematology, chemistry, coagulation, urinalysis.)” |
| Secondary endpoint | “Vital sign measurements.” |
Protocol definition of a clinically significant hearing change
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment and enrollment closure in January 2021
Description of analysis sets
Registry analysis population for baseline, outcome, and adverse event data
| Field | Registry record |
|---|---|
| Baseline, outcome, and adverse event analysis population | “All enrolled participants” |
Protocol statistical methods: descriptive statistics without imputation
Results
Participant disposition
Registry participant flow and reasons for not completing
Baseline characteristics
Registry baseline demographics
| Characteristic | Treatment naive (n=9) | Previously treated (n=18) | Total (n=27) |
|---|---|---|---|
| Age, mean (SD), years | “12.33(8.718)” | “17.94(13.705)” | “16.07(12.388)” |
| Female, participants | “4” | “7” | “11” |
| Male, participants | “5” | “11” | “16” |
| Hispanic or Latino, participants | “1” | “0” | “1” |
| White, participants | “7” | “17” | “24” |
| Black or African American, participants | “0” | “1” | “1” |
| Race unknown or not reported, participants | “2” | “0” | “2” |
Efficacy results
Efficacy and patient-reported outcome assessments not collected under the amended protocol
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
All-cause mortality and serious adverse events by preferred term
| Event | Treatment naive | Previously treated |
|---|---|---|
| All-cause mortality | “0/9 (0.00%)” | “0/18 (0.00%)” |
| Any serious adverse event | “5/9 (55.56%)” | “9/18 (50.00%)” |
| Deafness | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Pneumonia | “1/9 (11.11%)” | “2/18 (11.11%)” |
| Pneumonia aspiration | “0/9 (0.00%)” | “2/18 (11.11%)” |
| Acute respiratory failure | “2/9 (22.22%)” | “0/18 (0.00%)” |
| Respiratory distress | “0/9 (0.00%)” | “1/18 (5.56%)” |
| Hypoxia | “0/9 (0.00%)” | “1/18 (5.56%)” |
| Meningitis | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Staphylococcal bacteraemia | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Seizure | “1/9 (11.11%)” | “3/18 (16.67%)” |
| Ataxia | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Sedation | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Vomiting | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Post procedural haemorrhage | “0/9 (0.00%)” | “1/18 (5.56%)” |
| Femur fracture | “1/9 (11.11%)” | “0/18 (0.00%)” |
| Acute kidney injury | “0/9 (0.00%)” | “1/18 (5.56%)” |
Selected other (non-serious) adverse events reported at a 5% frequency threshold
| Event | Treatment naive | Previously treated |
|---|---|---|
| Any other adverse event | “9/9 (100.00%)” | “17/18 (94.44%)” |
| Hypoacusis | “2/9 (22.22%)” | “4/18 (22.22%)” |
| Deafness | “0/9 (0.00%)” | “2/18 (11.11%)” |
| Deafness neurosensory | “0/9 (0.00%)” | “2/18 (11.11%)” |
| Fatigue | “6/9 (66.67%)” | “7/18 (38.89%)” |
| Ataxia | “5/9 (55.56%)” | “6/18 (33.33%)” |
| Vomiting | “4/9 (44.44%)” | “4/18 (22.22%)” |
| Headache | “3/9 (33.33%)” | “2/18 (11.11%)” |
| Back pain | “3/9 (33.33%)” | “0/18 (0.00%)” |
| Pyrexia | “3/9 (33.33%)” | “3/18 (16.67%)” |
| Somnolence | “0/9 (0.00%)” | “4/18 (22.22%)” |
| Seizure | “2/9 (22.22%)” | “1/18 (5.56%)” |
| Upper respiratory tract infection | “3/9 (33.33%)” | “8/18 (44.44%)” |
Study limitations
Summary: design limitations of VTS-270-001
- Control and blinding: VTS-270-001 was a non-randomized, open-label, single-arm trial with masking recorded as none; the protocol used no control product and no data monitoring committee.
- Sample size and population: the protocol anticipated approximately 60 subjects from 30 sites, and no new subjects could enroll after 20 January 2021. The trial enrolled 27 participants (9 treatment-naïve and 18 previously treated through the expanded access program) aged 4 to 43 years. Treatment-naïve participants started at 400 mg, previously treated participants continued at their current stable dosage, and dose increases stopped as of Amendment 2 (21 April 2021).
- Missing efficacy collection: under the amended protocol, efficacy assessments (NPC-SS and clinician CGIC) and the EQ-5D-3L were not collected or analyzed, and auditory brainstem responses were not collected as of 20 January 2021.
- Analysis: data were summarized with descriptive statistics, with no hypothesis testing and no imputation of missing data.
- Early termination: the trial was terminated early when the sponsor determined that the benefit-risk profile of adrabetadex was not favorable, and treatment was allowed to continue up to 20 October 2021. Of 27 participants, 1 treatment-naive and 2 previously treated participants completed; study termination by the sponsor accounted for 2 and 10 participants. After 21 June 2021, continuation required the investigator to assess that the subject was benefiting from treatment.
- Sponsor statements: the protocol states that a comprehensive evaluation of all available clinical data “shows no clear evidence of benefit of adrabetadex in the treatment of neurologic symptoms of NPC” and that “the benefit/risk balance is negative.”
Prior sponsor's benefit-risk conclusion stated in the protocol, June 2021
Expanded access program
Objective
Purpose of the original Rush expanded access protocol
“The protocol was developed to allow access to treatment for 001-01, who was showing relatively rapid disease progression and could not enroll in the phase 1/2a trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this study, the long-term effects of intrathecal HPβCD treatment for 2.5–3 years in humans with NPC were evaluated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Objective of the survival analysis by baseline disease burden
Objective of the prompt versus delayed treatment analysis
Objective of the combination therapy analysis
Location and study date
Expanded access protocol under IND 119856 at Rush University Medical Center, with drug provided by Mandos Health
“Intrathecal adrabetadex was administered under an expanded access protocol (IND 119856) and reliance agreement with NIH approved by the Rush University Medical Center IRB.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“EBK has received funds to consult and/or run clinical trials for commercial programs focused in NPC including Orphazyme, Zevra, Intrabio, Vtesse, Sucampo, Mallinckrodt, and runs an expanded access program for adrabetadex for which drug is provided by Mandos Health.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Institutional review board approval of the original protocol
Evaluation sites for expanded access participants in a biomarker study
Agreement with the FDA to continue the program beyond October 2021
Data cutoff of the combination therapy analysis
Study design
Label description of the expanded access program data
Intermediate-size patient population IND modeled on the phase 1/2a trial
“In order to treat her brother, 001-02, at the same time, the expanded access application was submitted to FDA as an intermediate-size patient population IND (IND 119856).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The protocol was designed to parallel the ongoing phase 1/2a trial, with 2-week dosing intervals as opposed to the 4-week intervals in the phase 1/2a trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We report here results from three patients treated with IT HPβCD via expanded access through an intermediate-size patient population IND.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety data collection in the combination therapy analysis
Prompt versus delayed treatment analysis of participants treated for at least 5 years
Survival analysis of pooled clinical study and expanded access participants by baseline disease burden
Sibling case report design
Eligibility criteria
Access for patients unable to enroll in trials
“These protocols included a natural history/observational study (NCT00344331), phase I/II and phase II/III studies of intrathecal VTS‐270/adrabetadex (NCT01747135 and NCT02534844), and an expanded access program for access to intrathecal VTS‐270/adrabetadex for patients with NPC1 who were unable to enroll in trials (IND 119856).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trial ineligibility of the first three expanded access patients
“At age 13 she screened for the phase 1/2a trial of IT HPβCD but was ineligible due to multiple anticonvulsants and vagal nerve stimulator use.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“He was not able to enter the phase 1/2a trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“001-03 could not enter the phase 1/2a trial of HPβCD as it was closed when the family requested screening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Continued-benefit criteria for participants leaving the VTS301 trial, December 2021
Age criteria expanded to 3 months to 25 years, September 2024
Treatment
Label dosing in the expanded access program
Titration ceilings of the initial and revised expanded access protocols
Formulation, route, and dose range of the original Rush protocol
“A formulation of HPβCD with a specific chemical fingerprint was obtained from Janssen Research & Development, LLC initially and then Vtesse, Inc. (VTS-270, same formulation) and in all cases was administered by intrathecal infusion via lumbar puncture every two weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The initial protocol was written to dose escalate from 200 mg to 400 mg (accepted dose range at the time) over 4 months based on safety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The protocol was amended to allow dosing based on tolerability within a range from 200 mg-1200 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Doses and dosing intervals in a long-term treated cohort
“Intrathecal doses of adrabetadex at the time of sample collection ranged from 300–900 mg (mean 660 ± 216 mg).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interval between doses was either 2 weeks (n=6) or 4 weeks (n=4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Doses in the sibling case report
Study outcomes
Rationale for using rescored 4-domain NPC clinical severity scale as the disease progression outcome
Domains of the rescored 4-domain scale and burden quartiles
Hearing items excluded from severity scores because of cyclodextrin ototoxicity
“Hearing items were scored at baseline to evaluate disease severity, but efficacy assessment scores excluded hearing and auditory brainstem response items, as hearing loss is a known side effect of HPβCD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Participants enrolled, December 2021
| Field | Dashboard |
|---|---|
| Current patients enrolled in Expanded Access Program | “50 patients” |
Participants in the survival analysis by baseline disease burden
Participants in the long-term 24(S)-hydroxycholesterol study
Description of analysis sets
Baseline definitions and survival comparisons in the disease burden analysis
Combination therapy analysis groups and observation time
| Group (participants) | Definition |
|---|---|
| Adrabetadex first (28) | “Participants who started adrabetadex prior to adding levacetylleucine and/or arimoclomol” |
| Any combination exposure (33) | “Participants who had exposure to levacetylleucine and/or arimoclomol at any point” |
| No combination after adrabetadex (53) | “Participants with no record of starting arimoclomol and/or levacetylleucine after starting adrabetadex” |
Statistical tests in the long-term 24(S)-hydroxycholesterol study
Results
Participant disposition
Duration of treatment and follow-up in the 2026 analyses
Time on treatment in the long-term 24(S)-hydroxycholesterol cohort
Time since first dose and discontinuations in the expanded access program
| Measure | All EAP (n=86) |
|---|---|
| Time since first treatment dose, median [IQR], months | “52.8 [15.4, 74.2]” |
| TEAE leading to discontinuation, n (%) | “3 (3.5)” |
| TEAE leading to death, n (%) | “6 (7.0)” |
Baseline characteristics
Baseline characteristics of all expanded access participants
| Characteristic | All EAP (N=86) |
|---|---|
| Neurological onset <2 years, n (%) | “26 (30.2)” |
| Neurological onset 2 to 6 years, n (%) | “23 (26.7)” |
| Neurological onset ≥6 years, n (%) | “29 (33.7)” |
| Age at onset missing, n (%) | “8 (9.3)” |
| Age at neurological symptom onset, median (Q1, Q3), years (n=78) | “3.5 (1.5, 7.0)” |
| Age at adrabetadex treatment start, median (Q1, Q3), years (n=78) | “8.0 (3.0, 20.0)” |
| Male, n (%) | “51 (59.3)” |
| Female, n (%) | “34 (39.5)” |
| White, n (%) | “76 (88.4)” |
| Miglustat use at baseline, yes, n (%) | “33 (38.4)” |
| Miglustat use at baseline, no, n (%) | “46 (53.5)” |
Baseline characteristics of treated participants with infantile onset in the disease burden analysis
| Characteristic | Overall (N=76) |
|---|---|
| Neurological onset <2 years, n (%) | “33 (43.4)” |
| Neurological onset 2 to <6 years, n (%) | “43 (56.6)” |
| Age at neurological symptom onset, mean (SD), years | “2.5 (1.56)” |
| Age at adrabetadex treatment start, mean (SD), years | “7.7 (5.56)” |
| Age at adrabetadex treatment start, median (Q1, Q3), years | “6.2 (3.2, 10.8)” |
| Male, n (%) | “41 (53.9)” |
| White, n (%) | “66 (86.8)” |
| Baseline R4DNPCCSS, mean (SD) | “7.2 (5.06)” |
| Baseline R4DNPCCSS, median (Q1, Q3) | “7.0 (3.0, 10.0)” |
Baseline characteristics by time from onset to treatment
| Characteristic | Treatment initiation <1 year from onset (n=9) | Treatment initiation ≥1 year from onset (n=16) |
|---|---|---|
| Age at neurological symptom onset, mean (SD), years | “2.11 (1.563)” | “2.65 (1.494)” |
| Age at adrabetadex treatment start, mean (SD), years | “2.70 (1.614)” | “7.15 (3.838)” |
| Duration from onset to treatment, mean (SD), years | “0.59 (0.324)” | “4.50 (3.308)” |
| Miglustat use at baseline, yes, n (%) | “1 (11.1)” | “9 (56.3)” |
| Baseline R4DNPCCSS, median (Q1, Q3) | “1.50 (0.50, 2.50)” | “5.00 (2.00, 10.00)” |
| Duration of treatment exposure, mean (SD), weeks | “348.37 (54.297)” | “397.23 (93.427)” |
Characteristics of the long-term 24(S)-hydroxycholesterol cohort
“This cohort included 7 males and 3 females.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean and median age were 20.1 ± 7.8 and 24.1(range 8.7–29.0) years, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean and median ANO were 7.3 ± 4.1 and 6.8 (range 0–13) years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Characteristics of the first three expanded access patients at entry
Efficacy results
Company-presented survival by baseline disease burden, pooled clinical study and expanded access participants
| Median OS (95% CI), months | Minimal quartile | Mild quartile | Moderate quartile | Severe quartile |
|---|---|---|---|---|
| Adrabetadex-treated participants | “NE (NE, NE)” | “136 (88, NE)” | “75 (60, NE)” | “55 (12, NE)” |
| Untreated cohort | “99 (39, 192)” | “111 (62, NE)” | “62 (28, NE)” | “29 (11, NE)” |
Company summary of the CNS 2026 survival and progression analyses
Time from onset to treatment in the prompt and delayed treatment groups
Sibling case report: early and delayed treatment initiation
Neurological outcomes in the first three expanded access patients over 2.5 to 3 years
“No worsening in any domain except eye movements (vertical pursuit gain) was seen for any of the three patients, and in the other domains, improved scores on measures were seen over time for one or more patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The NSS showed stable to slightly improved ratings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All three patients have shown substantial improvement in oral and pharyngeal phases of swallowing function as rated by the MBSImp (Table 4; Figure 6) and PAS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CSF 24(S)-hydroxycholesterol response after more than 4 years of treatment
“Mean pre-drug administration CSF 24(S)OHC level was 0.27 ± 0.20 ng/ml.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean CSF 24OHC level 48 hours after IT adrabetadex administration increased to 0.43 ± 0.22 ng/ml.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This 1.6-fold average increase was significant (p=0.0289, paired t-test).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“24(S)OHC levels increased in 7 of the 10 individuals and the mean increase was 0.28 ± 0.34 ng/ml.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CSF neurofilament light chain in a cohort including expanded access participants
“The population was derived from an observational/natural history study at the NIH Clinical Center in Bethesda, Maryland (NCT00001367), from a phase I/II intrathecal trial of adrabetadex (NCT01747135), from a phase II/III intrathecal trial of adrabetadex (NCT02534844) and from individuals receiving intrathecal adrabetadex through an expanded access program (IND 119856).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By the last visit, 49 (42.2%) were on HPβCD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over time, we did not observe a protective effect of HPβCD on NfL levels (OR=1.25, 95% CI 0.99–1.58) (Supplementary Figure 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In fact, when adjusting the longitudinal data for the protective effect of miglustat, HPβCD was associated with increased NfL levels (OR=1.35, 95% CI 1.09–1.67).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CSF total tau in a cohort including expanded access participants
“The data set consisted of 262 measurements from 101 individuals with NPC1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intrathecal 2HPβCD therapy was associated with a reduction in CSF total Tau levels of 19% (FDR‐adjusted p = 0.008).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CSF neuron-specific enolase in expanded access participants
“Paired CSF and serum samples were obtained from a subset of ten participants receiving IT HPβCD every 2–4 weeks under the EAP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants on IT HPβCD experienced an average decrease of 3.7 ± 2.9 ng/mL in CSF NSE levels per year, while those not on IT HPβCD showed an average annual increase of 2.6 ± 2.5 ng/mL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This difference was statistically significant (p = .0317), suggesting that IT HPβCD treatment may reduce CSF NSE levels over time (figure 4b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
School and work functioning in the first three expanded access patients
“001-02 has had stable school performance and graduated high school with a regular curriculum and some accommodations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“001-03 has had stable performance in a community college and subsequent job training program and does well with office work.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Treatment-emergent adverse events in the expanded access program by combination therapy group
| Measure | Adrabetadex first, adrabetadex-only period (n=28) | Any combination exposure, combination period (n=33) | No combination after adrabetadex (n=53) | All EAP (n=86) |
|---|---|---|---|---|
| With ≥1 TEAE (any grade), n (%) | “28 (100)” | “23 (69.7)” | “48 (90.6)” | “81 (94.2)” |
| Leading to death, n (%) | “0” | “1 (3.0)” | “5 (9.4)” | “6 (7.0)” |
| Serious AEs, n (%) | “13 (46.4)” | “8 (24.2)” | “24 (45.3)” | “41 (47.7)” |
| Grade ≥3, n (%) | “9 (32.1)” | “6 (18.2)” | “21 (39.6)” | “33 (38.4)” |
| TEAEs of interest, n (%) | “22 (78.6)” | “9 (27.3)” | “35 (66.0)” | “62 (72.1)” |
| Ataxia, n (%) | “10 (35.7)” | “5 (15.2)” | “23 (43.4)” | “37 (43.0)” |
| Fatigue, n (%) | “17 (60.7)” | “7 (21.2)” | “25 (47.2)” | “47 (54.7)” |
| Hearing impairment, n (%) | “10 (35.7)” | “2 (6.1)” | “15 (28.3)” | “26 (30.2)” |
Hearing loss, post-dose ataxia and tiredness, and lumbar puncture events in the first three expanded access patients
“Aside from hearing changes and post-dose tiredness/ataxia known to be associated with higher doses of HPβCD, adverse events have been predominantly unrelated to the lumbar punctures (LPs) or HPβCD (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Post-LP headaches and nausea in 001-01 and 001-02 for several initial doses essentially resolved after switching to the Whitacre needle for LPs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was persistent ataxia and tiredness at 1200 mg (Table 3) and milder post-dose ataxia and tiredness at 900 mg, lasting 3–7 days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“She continues on a dose of 300 mg (Table 3) due to an incremental hearing loss and tinnitus with each of three 400 mg doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“001-03 has an unusual sensitivity to hearing loss with HPβCD, as the extent of hearing loss seen in this patient at the 400 mg dose, is not known to have been observed in any other patient worldwide.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: design limitations of the expanded access program analyses
- Control and setting: the original report of three patients names as limitations “the lack of a control group” and treatment through an expanded access protocol with likely more confounding changes from optimizing support and other treatments than in a clinical trial. Enrollment required that participants be ineligible for all currently enrolling clinical trials.
- Population counts: the prescribing information describes 85 participants (71 treatment-naïve and 14 previously treated) with a mean (SD) treatment duration of 44 (32) months.
- Dosing: doses started at 200 mg or 400 mg based on age, with titration up to 1200 mg in the initial protocol or 900 mg in the later revision, and dose adjustments were allowed.
- External comparison and analysis sets: the survival analysis by baseline disease burden compared 80 adrabetadex-treated participants with I-NPC (neurological onset <6 years) from clinical studies or the expanded access program with an untreated cohort of 44 from the NIH natural history study. Four treated participants without a baseline R4DNPCCSS score were excluded, leaving 76. Baseline was the last observation before the first dose for treated participants and the first available observation for the untreated cohort, and the authors state that “no matching procedure was performed between treated and untreated participants.”
- Prompt versus delayed treatment: the analysis included only participants with onset <6 years of age who had sustained treatment for at least 5 years, 9 with treatment initiation <1 year and 16 with initiation ≥1 year from onset, and miglustat use at baseline was 1 (11.1%) and 9 (56.3%), respectively. The company compared progression in these 25 participants with published natural history data.
- Combination therapy analysis: participants exposed to combination therapy had a shorter time since first treatment dose, as most started those therapies when they became commercially available at the end of 2024. Safety data were collected only while participants were in the study and receiving adrabetadex, and were not available for other NPC therapies received before enrollment.
- Concomitant miglustat: all three patients in the original report went on miglustat at the same age as diagnosis, and its authors state that an effect of miglustat or of the combination on progression cannot be ruled out. In the CSF neuron-specific enolase study, most participants receiving intrathecal HPβCD were also on miglustat, which the authors state makes it challenging to attribute the decrease to HPβCD alone.
- Sample size: the long-term 24(S)-hydroxycholesterol study included 10 individuals, and its authors state that its conclusions are limited by its small size; the CSF neuron-specific enolase study used a subset of ten expanded access participants.
Authors' limitations of the original expanded access report
“Limitations of this work include the lack of a control group and treatment through an expanded access protocol in which there are likely more confounding changes due to optimizing support and other treatments than would be seen in a clinical trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“it is impossible to rule out an effect on progression of the Miglustat or a combined effect of Miglustat and HPβCD, which target lipid storage in NPC via different mechanisms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unmatched comparison with the untreated cohort in the disease burden analysis
Shorter observation time in the combination therapy group
Small cohort size and concomitant miglustat in the biomarker studies
“The conclusions of this study are limited by its small size; however, the data presented herein suggest that 24(S)OHC remains a robust proximal pharmacodynamic biomarker in individuals who have been treated for over four years with IT adrabetadex.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NIH phase 1-2a trial
Objective
Trial objectives: safety, tolerability, feasibility, pharmacokinetics, and active dose
Primary objective of safety and primary pharmacodynamic objective of 24(S)-hydroxycholesterol response
“Safety and tolerability of HPβCD was the primary objective, and 24(S)-hydroxycholesterol (24(S)-HC) response was the primary pharmacodynamic objective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Here we present the ad-hoc analysis of an 18-month non-randomized, open-label, phase 1/2a trial to determine safety and potential efficacy of escalating doses of lumbar intrathecal HPβCD in NPC1 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Objective of the 36-month neuropsychological follow-up analysis
“The objective of this current analysis was to evaluate the change in neurodevelopmental outcomes at up to 36 months post-baseline in this Phase 1/2a trial of escalating doses of lumbar intrathecal HPβCD in NPC1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Registry dates, enrollment, and single study location
| Field | Quoted record |
|---|---|
| Study start | “2013-01” |
| Primary completion (actual) | “2017-03” |
| Study completion (actual) | “2017-03” |
| Location | “National Institutes of Health Clinical Center, 9000 Rockville Pike” |
| City and state | “Bethesda, Maryland, United States, 20892” |
IND submission in December 2012 and trial start in February 2013
Enrollment periods at the NIH Clinical Center and Rush University Medical Center
“NIH participants were enrolled between September 2013 and January 2015. RUMC participants were enrolled between December 2013 and June 2014.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both the phase 1/2a trial of HPβCD (13-CH-0001) and the NPC1 NHx trial (06-CH-0186) were approved by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Institutional Review Board.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Label description of Trial 2: 78-week, non-randomized, open-label, single-center dose escalation trial
Registry design: phase 1, non-randomized, open-label, single-center study with 3-patient dose cohorts
Open-label dose escalation with a natural history comparison cohort and a parallel every-two-week cohort at RUMC
“An open-label, dose-escalation study was conducted to evaluate safety, pharmacodynamics, and efficacy of monthly intrathecal doses of 50–1200 mg of a well-characterized HPβCD mixture with a specific compositional fingerprint and limits for impurities (appendix p 3, VTS-270, Vtesse Inc., Gaithersburg MD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“To explore the potential effect of every two week dosing, three additional participants were enrolled in a parallel study at Rush University Medical Center (RUMC, appendix p 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Clinical efficacy was ascertained by comparing NSS progression in the 14 NIH HPβCD-treated participants to that observed in a historical cohort of 21 participants of similar age range (table, appendix figure 3, p 12) followed in a NHx study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Choice of the lumbar intrathecal route
“We elected to use lumbar intrathecal administration since HPβCD does not efficiently cross the blood-brain-barrier” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, intrathecal administration avoids potential pulmonary toxicity associated with high-dose systemic delivery” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Original plan for intracerebroventricular delivery and adaptive dose escalation design
“Pre-clinical studies were therefore directed towards supporting ICV administration of HP-β-CD in the Phase I trial using an Ommaya reservoir for delivery, Table (1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Phase I trial is an adaptive, dose escalation study designed to systematically determine a safe and biochemically effective dose of HP-β-CD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study oversight and investigator IND transferred to Vtesse
“Study monitoring was provided by a study safety committee and an independent Data Safety Monitoring Board. Independent auditing was provided by Amarex Clinical Research (Gaithersburg, MD). An investigator IND supported the study (IND 113273). This IND was subsequently transferred to Vtesse, Inc. (Gaithersburg, MD) to support further drug development.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Funding, study drug supply, and role of the funders
“The funders had no role in study design, data collection, data analysis or decision to submit for publication. Janssen Research & Development, a Johnson and Johnson company provided the study drug and both Janssen Research & Development and Johnson and Johnson provided probono preclinical development support. Vtesse Inc. supported statistical analysis by Statistics Collaborative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICHD-led design, data collection, and analysis
Use of the trial data for Breakthrough Therapy designation and the phase 2b/3 trial
“Data from this trial have been accepted by the FDA to support a Breakthrough Drug designation for VTS-270, and have supported the development and implementation of a randomized, sham-controlled, pivotal phase 2b/3 trial approved by both the FDA and EMA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Inclusion criteria: age, NPC1 diagnosis, neurological manifestation, and stable miglustat dose
Exclusion criteria: severe or asymptomatic disease, prior cyclodextrin, and conditions affecting lumbar puncture or audiology
Eligible ages and onset category of enrolled participants
“Eligible participants were aged 2 – 25 years and neurological manifestations, although participants were excluded if these were severe. All participants had neurological symptoms by 13 years of age thus would be categorized as childhood/adolescent onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis by clinical, cellular, and molecular criteria and selection of the comparison cohort
“The diagnosis of NPC1 disease was established by a combination of clinical, cellular and molecular criteria (appendix pp 2–3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The NIH NHx population was used as the comparison group, and participants were selected based on two criteria: the presence of two or more assessments within a 25 month time period and an age range of 4 to 24 years at the first of any two or more assessments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Label description of Trial 2 dosing: 200 to 1,200 mg once monthly
Formulation, infusion volume, starting doses, and mean doses at 12 and 18 months
“HPβCD was formulated as a 20% solution and diluted in saline to provide an infusion volume of 10 ml, which was infused over 2–3 minutes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“HPβCD was administered monthly by lumbar intrathecal infusion for the NIH participants. Dosing for CDA101–112 was initiated at 50, 200, 300, or 400 mg HPβCD in groups of 3 participants, and the dose (appendix figure 2, p 11) was advanced based on tolerance and safety data from higher dose cohorts. Mean doses at 12 and 18 months were 289 ± 68 mg and 423 ± 142 for CDA101–112, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CDA113 and CDA114 were dosed at 900 mg for 12 months. HPβCD was administered every two weeks to the RUMC cohort and their mean dose at 18 months ranged from 297 to 481 mg (figure 1B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sequential starting-dose assignment and escalation to 600 or 1200 mg
“HPβCD (VTS-270) was formulated and provided by Johnson & Johnson (Janssen Research and Development).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were sequentially assigned to starting doses of 50 mg (CDA101–103), 200 mg (CDA104–106), 300 mg (CDA107–109), and 400 mg (CDA110–112). Two participants (CDA113–114) were initially dosed at 900 mg. After initial dosing, participants were dose-escalated (to 600 or 1200 mg) as tolerated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose increase for all participants after high doses were tolerated
Study outcomes
Rationale for using plasma 24(S)-Hydroxycholesterol area under the curve as the primary endpoint
Registered primary and secondary outcome measures
| Outcome role | Outcome measure | Time frame |
|---|---|---|
| Primary | “24-hydroxycholesterol Area under the curve” | “Days” |
| Secondary | “Hearing loss.” | “Year” |
Plasma 24(S)-hydroxycholesterol as a neuron-derived pharmacodynamic marker of cholesterol homeostasis
“In preclinical studies, treatment with HPβCD was shown to redistribute lysosomal cholesterol, resulting in modulation of a range of central nervous system (CNS) sterol homeostatic responses, including synthesis of 24(S)-HC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“measurement of 24(S)-HC in response to HPβCD provides a pharmacodynamic marker of improved neuronal cholesterol homeostasis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Plasma 24(S)-HC concentrations were determined at pre-dose, 8, 24, 30, 48, and 72 hours post-dose after either saline or HPβCD infusion and the area under the curve was determined (AUC8–72).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Biochemical efficacy defined as change from baseline in plasma 24(S)-hydroxycholesterol
Secondary efficacy endpoint: NPC Neurological Severity Score
“Clinical efficacy was evaluated using the NSS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NPC1 disease progression has been characterized using the NPC Neurological Severity Score (NSS). The NSS is a Likert-like scale that assesses severity of clinically relevant signs and symptoms in nine major and eight minor domains (appendix, p 10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Development of the severity scale and linear progression independent of age of onset
“The absence of a universally accepted clinical outcome measure is an impediment to the design of a therapeutic trial for NPC. Thus, we developed a clinical severity scale to characterize and quantify disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Longitudinal chart review of historical data demonstrated that although age of onset varied significantly, the rate of progression appeared linear, independent of age of onset, and similar in all patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory CSF biomarkers of neuronal damage: FABP3 and calbindin D
“CSF levels of fatty acid binding protein 3 (FABP3) and calbindin D were assayed by Myriad Rules Based Medicine (Austin, TX).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Elevated FABP3 has been reported as a biomarker for neurodegenerative disorders” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neither calbindin D nor FABP3 have been established as clinical surrogates, but our observation that CSF levels decrease in temporal relationship with HPβCD therapy is consistent with the conclusion that intrathecal HPβCD decreases neuronal damage in NPC1 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neuropsychological outcomes in the 36-month follow-up: IQ and adaptive behavior
“The primary neurocognitive outcomes in this study were IQ and adaptive behavior.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While conclusions regarding changes over time are limited overall, the presentation of data from various measures and types of scores suggest that the adaptive behavior age equivalent scores are the most clinically useful scores for studies of this nature.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Fourteen participants treated monthly and three treated every two weeks, with no formal sample size calculation
“Intrathecal doses ranging from 50–1200 mg were evaluated in 14 neurologically affected NPC1 participants treated monthly for 12 to 18 months. Three additional participants were treated every two weeks for 18 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No formal calculation of sample size was made for ad-hoc analysis of the NSS, and given the small sample size we are not estimating confidence intervals.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No a priori power calculation for the neuropsychological analyses
“No a priori power calculation was performed for these analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The sample size in this study is just commensurate with the minimum suggested for valid interpretation of fixed effects and variance (n ≈ 15), but is below that suggested for the standard errors of the fixed effect (n ≈ 30)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Post hoc mixed model repeated measures analysis of annualized NSS slope versus the natural history cohort
“A post hoc mixed model repeated measures approach was used to assess the efficacy of HPβCD in this population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary analysis estimates the slope as change in score per year from a mixed model repeated measures (MMRM) model with time, group (HPβCD-treated participants or NIH NHx study participants), and a group by time interaction term.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Responder analysis based on change from baseline in each NSS domain
“For the responder analysis, a change from baseline was used to assess the efficacy of HPβCD in individual participants. The NIH NHx population was used as the comparison group; the subject selection criteria were as described for the MMRM approach.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fisher’s exact test was used for the responder analysis. Unless otherwise specified, data are expressed as mean ± SEM and a nominal p-value of 0.05 was considered significant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Audiometric analysis set
“Behavioral thresholds for pure-tone stimulation could be established for 12/14 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Behavioral audiograms could not be obtained on participants CDA112 and CDA113 due to inability of these participants to perform this testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neuropsychological analysis set: participants with any available data
“Participants with any available data were included in analysis; list-wise deletion was not used. However, where missing data resulted in a sample size <10 at more than one major assessment point, parametric analysis was not performed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No comparison group was available, so the goal of this set of analyses was to describe the course of the neuropsychological outcomes during the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Timing of the final NSS evaluation by participant
“NSS evaluations were at 18 months for participants CDA101 and CDA103–111. The 18-month evaluation for CDA112 was obtained at 19 months. NSS data corresponding to CDA102, CDA113 and CDA114 were obtained at 12 months and data corresponding to the three RUMC participants were obtained at 18 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Enrollment of participants at the NIH Clinical Center (n=14) between September 2013 and January 2015 and participants at RUMC (n=3) between December 2013 and June 2014.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Follow-up to 36 months for neuropsychological outcomes
“This analysis includes outcomes collected out to 36 months post-baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fewer than 10 WRAML observations were available at most timepoints (including baseline), so these data were not subjected to parametric analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Baseline characteristics of the NIH treated cohort and the natural history comparison cohort
Comparability of the treated and natural history cohorts at baseline
Baseline hearing loss in all participants
Participant information for the 14 NIH participants in the neuropsychological follow-up
| Characteristic | Mean ± standard deviation | Range |
|---|---|---|
| Age at diagnosis (years) | “9.07 ± 5.65”View highlighted excerpt for this quote | “2 − 20”View highlighted excerpt for this quote |
| Age at baseline (years) | “15.07 ± 5.53”View highlighted excerpt for this quote | “4 − 23”View highlighted excerpt for this quote |
| Niemann-Pick Type C1 Total Severity Score at Baseline | “19.29 ± 7.46”View highlighted excerpt for this quote | “5 − 32”View highlighted excerpt for this quote |
| Characteristic | n (%) |
|---|---|
| Female | “7 (50%)”View highlighted excerpt for this quote |
| White | “14 (100%)”View highlighted excerpt for this quote |
| Non-Latino/Non-Hispanic | “13 (93%)”View highlighted excerpt for this quote |
| Hearing loss at baseline | “11 (79%)”View highlighted excerpt for this quote |
| Seizures | “5 (36%)”View highlighted excerpt for this quote |
| Miglustat | “11 (79%)”View highlighted excerpt for this quote |
Efficacy results
Plasma 24(S)-hydroxycholesterol response after intrathecal dosing
“The majority (121/155) of post-drug plasma 24(S)-HC AUC8–72 values were greater than post-saline values; however, plasma responses were more variable and less robust compared to what was observed in preclinical testing (appendix figure 4A, pp 13–14).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Despite the variability, the data suggested a trend for increased 24(S)-HC response at higher doses and significant increases in individual subject responses were observed at 900 and 1200 mg (figures 2A and2B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each paired set of pre/post values represents an individual dose: for 900 mg, n=18 doses among 8 subjects; for 1200 mg, n=13 doses among 7 subjects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CSF 24(S)-hydroxycholesterol response in three participants
“The CSF 24(S)-HC concentrations in three participants treated with 600–900 mg of HPβCD were increased over two-fold” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, the increase in CSF 24(S)-HC concentration after HPβCD administration was unambiguous.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CSF FABP3 and calbindin D decreased from baseline
“Significant decreases were observed when comparing baseline and final CSF FABP3 (D) and calbindin D (E) levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We also observed that CSF calbindin D and FABP3 levels, biomarkers of neuronal damage, decreased significantly in the majority of HPβCD-treated participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data provide evidence that treatment with HPβCD shifts, towards normal, CSF biomarkers of CNS pathology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Annualized total NSS progression versus the natural history comparison cohort, as printed in the author manuscript
“The total NSS for the 14 participants treated monthly increased at a slower rate of 122 ± 0 34 points/year compared to 2 92 ± 0 27 points/year (p=0 0002) for the comparison cohort (figure 4A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data demonstrate a significant reduction in disease progression in the HPβCD-treated cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NSS domains: decreased progression in ambulation, cognition, and speech and increase in hearing
“Annualized rate of disease progression is decreased for ambulation, cognition, and speech in the intrathecal HPβCD-treated participants in comparison to the NHx group. Only the hearing subdomain demonstrated a notable annualized increase in progression in the HPβCD-treated group. This is consistent with the known ototoxicity of HPβCD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Responder analysis: 7 of 14 treated participants versus 21 of 21 comparison participants progressed
“Individuals with a decreased or stable NSS minus hearing were considered to be responders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the NHx cohort 21/21 (100%) demonstrated disease progression (figure 4C); whereas, 7/14 (50%) of the participants in the HPβCD-treated group demonstrated disease progression (figure 4D). The RUMC participants treated every 2 weeks were all responders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, a responder analysis showed decreased or stabilized NSS in 10/17 HPβCD-treated participants while 21/21 comparison subjects demonstrated disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Individual pre-treatment and on-treatment NSS in eight participants
“Individual pre/post NSS for eight participants where pretrial data were available are provided in appendix figure 6 (pp 17–18). Stabilization or slowing of NPC1 disease progression can be appreciated in six of eight participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sensitivity analyses: miglustat-treated participants and inclusion of the every-two-week RUMC cohort
“Sensitivity analyses showed similar results when the analysis was restricted to participants treated with miglustat and were suggestive of increased efficacy with every two week dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The limited data available from the RUMC participants suggests that every two week dosing may be more effective than monthly dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intelligence quotient over 36 months
“The average annualized change in FSIQ was negative: B = −1.28, SE = 0.70, t(34.2) = −1.83, p =0 .076. The slopes in each of the IQ subdomains were weaker: NVIQ, B = −0.65, SE = 0.82, t(35.3) = −0.79, p = 0.43; VIQ, B = −0.80, SE = 1.02, t(34.3) = −0.79, p = 0.44.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Up to 36-months post-baseline, there were no significant declines in the areas of cognition and adaptive behavior.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In conjunction with previous findings, these results provide support for the slowing of disease progress up to 36 months post-initiation of intrathecal VTS-270.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma and CSF N-palmitoyl-O-phosphocholineserine in trial participants
“The plasma samples collected from NPC1 study participants in Phase 1/2a trial of IT HPβCD at pre-dosed time point in each visit were used to evaluate the long-term effect of IT HPβCD on PPCS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PPCS was decreased, increased, and unchanged in 44% (Figure 2B), 17% (Figure 2C), 33% of subjects (Figure 2D), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the IT HPβCD trial, the pre-treatment CSF samples supplied with 2% CHAPS that prevented absorption loss of PPCS were collected from only 2 study participants. CSF PPCS did not change after HPβCD treatment in these 2 individuals (Figure 3E).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Caregiver-interview measure of adaptive behavior: Vineland Adaptive Behavior Scales
“The Vineland is a semi-structured caregiver interview that assesses adaptive functioning in Communication, Daily Living Skills, Socialization, and Motor Skills (standard scores available only for children under the age of 7 years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vineland standard scores and age equivalents over 36 months
“On average, the Vineland-II ABC standard score decreased by 1.76 points per year [SE = 0.67, t(59.1) = −2.62, p = 0.011].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, examination of the average age equivalent scores (in months) for these domains (shown in Figure 2) indicated that the small decreases in standard scores were not due to worsening, but rather to slower-than-typical (or no) acquisition of skills.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Annualized slopes for each of the domain age equivalents were positive, although the 95% CI included zero: Communication [B = 0.71, SE = 3.12, t(60.7) = 0.23, p = 0.82], Socialization [B = 2.99, SE = 2.92, t(60.4) = 1.03, p = 0.30], Daily Living Skills [B = 2.76, SE = 2.76, t(60.3) = 1.18, p = 0.24], and Motor Skills [B = 1.42, SE = 0.94, t(50.5) = 1.51, p = 0.14].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect of treatment-related hearing loss on daily communication
Safety results
Safety assessment methods: CTCAE grading and monthly audiology
“Severity of adverse events was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. Audiological assessments were obtained monthly prior to each infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No drug-related serious adverse events; post lumbar puncture headache and ototoxicity as expected adverse events
“No drug-related serious adverse events were observed. Mid- to high-frequency hearing loss, an expected adverse event, was documented.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notable expected adverse events included participants with post lumbar puncture headache (64%, 9/14) and ototoxicity (100%, 14/14).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Transient post-dose unsteadiness and fatigue at doses above 600 mg
“Notable unexpected adverse events included post-administration unsteadiness and fatigue at doses above 600 mg. This was transient and typically occurred 24–72 hours after dosing. The degree of impairment was variable across participants, but classified as significant in 3/9, 6/12 and 9/9 participants at 600, 900 and 1200 mg, respectively. The unsteadiness and fatigue may variably attenuate with repetitive dosing at a given dose level.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From a safety standpoint, doses up to 1200 mg were generally well tolerated. The transient post-dose ataxia/fatigue observed in this study may be a dose-limiting side effect, especially if the dose or frequency of dosing is increased.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatocellular carcinoma in one participant
Additional mid- to high-frequency hearing loss in all participants
“After HPβCD administration, all participants demonstrated additional mid- to high-frequency hearing loss, and all participants were hearing aid candidates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Broad variation in the degree of ototoxicity in individual participants was observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These data suggest that there is greater HPβCD ototoxicity in individuals who have not yet lost hearing due to NPC1 disease itself.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At study end, all participants had functional deficits in hearing, but these deficits did not appreciably impact daily communication when managed with hearing aids.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Grade 3 hearing loss in one RUMC participant and tinnitus
“One subject (RUMC03) demonstrated marked sensitivity to HPβCD with CTCAE grade 3 hearing loss upon initial dosing at 400 mg; however, subsequent administration of 300 mg HPβCD every two weeks did not result in additional ototoxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although not every patient could reliably self-report tinnitus, it appeared to be associated with HPβCD administration. Tinnitus was limited to the post-dose time period in two cases, but persistent in four participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: design limitations of the NIH phase 1-2a trial
- Control and external comparison: the trial was a non-randomized, open-label, single-center dose escalation study. The authors state that it “relies on a historical comparison group, and is not a randomized, placebo-controlled trial.” Efficacy compared NSS progression in the 14 NIH participants with a historical cohort of 21 participants from a natural history study, selected for two or more assessments within 25 months and an age of 4 to 24 years. Natural history participants were on average younger and had lower NSS at baseline (mean total NSS 14.5 ± 9.7 versus 19.3 ± 7.5), differences the authors report as not significant.
- Analysis: the clinical efficacy data come from an ad-hoc analysis using a post hoc mixed model repeated measures approach. No formal sample size calculation was made, confidence intervals were not estimated given the small sample size, and the responder analysis used Fisher's exact test with a nominal p-value of 0.05.
- Dose escalation: the authors state that the dose escalation design limits the ability to establish dose-response correlations. The publication describes monthly doses of 50 to 1200 mg in the 14 NIH participants and every-two-week dosing in three additional participants at Rush University Medical Center; the prescribing information describes doses of 200 to 1,200 mg once monthly, regimens it does not recommend.
- Unequal follow-up and measurement: NSS data for three participants (CDA102, CDA113, and CDA114) were obtained at 12 months and for the others at 18 or 19 months. Behavioral audiograms could be obtained for 12 of 14 participants.
- Concomitant miglustat: 12 (86%) treated and 16 (76%) natural history participants used miglustat. In the 36-month neuropsychological analysis, 11 of 14 participants took miglustat at baseline and throughout, and the small number not taking it prevented assessment of its confounding effect.
- Neuropsychological follow-up: the analysis had no comparison or historical control group, was descriptive because the study was not designed to target neuropsychological efficacy, had no a priori power calculation, and had a sample below the n ≈ 30 suggested for the standard errors of the fixed effect. Fewer than 10 WRAML observations were available at most timepoints.
- Confirmation: the authors state that data from a randomized, sham-controlled phase 2b/3 study would be needed to confirm the results.
Limitations stated by the trial authors: historical comparison group, ad-hoc analysis, and dose escalation design
“This study has several limitations. First, it relies on a historical comparison group, and is not a randomized, placebo-controlled trial. Second, the clinical efficacy data is based upon an ad-hoc analysis. Third, the dose escalation design focused on determining safety and tolerability limits our ability to establish dose-response correlations with biomarker and clinical data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additional work is required to determine if ototoxicity can be separated from neurological efficacy; however, in the context of a lethal neurodegenerative disorder, the risk of functional hearing impairment that can be managed with hearing aids can be justified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Data from a multicenter, international, randomized, sham-controlled phase 2b/3 study will be needed to confirm the results of this study and obtain FDA and EMA approval.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of the 36-month neuropsychological analysis: no control group and concomitant miglustat
“Additionally, we were not able to include a historical control group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The descriptive nature of this report was necessary because the study was not designed to specifically target clinical efficacy with respect to neuropsychological functioning. Finally, 11 of 14 participants were taking miglustat at baseline and throughout the trial. Due to the small number of participants not taking miglustat, we were unable to ascertain its potential confounding effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote